4.6 Article

Acute Decline in Renal Function, Inflammation, and Cardiovascular Risk after an Acute Coronary Syndrome

Journal

Publisher

AMER SOC NEPHROLOGY
DOI: 10.2215/CJN.03510509

Keywords

-

Ask authors/readers for more resources

Background and objectives: Chronic kidney disease is associated with a higher risk of cardiovascular outcomes. The prognostic significance of worsening renal function has also been shown in various cohorts of cardiac disease; however, the predictors of worsening renal function and the contribution of inflammation remains to be established. Design, setting, participants, & measurements: Worsening renal function was defined as a 25% or more decrease in estimated GFR (eGFR) over a 1-mo period in patients after a non-ST or ST elevation acute coronary syndromes participating in the Aggrastat-to-Zocor Trial; this occurred in 5% of the 3795 participants. Results: A baseline C-reactive protein (CRP) in the fourth quartile was a significant predictor of developing worsening renal function (odds ratio, 2.48; 95% confidence interval, 1.49, 4.14). After adjusting for baseline CRP and eGFR, worsening renal function remained a strong multivariate predictor for the combined cardiovascular composite of CV death, recurrent myocardial infarction (MI), heart failure or stroke (hazard ratio, 1.6; 95% confidence interval, 1.1, 2.3). Conclusions: Patients with an early decline in renal function after an acute coronary syndrome are at a significant increased risk for recurrent cardiovascular events. CRP is an independent predictor for subsequent decline in renal function and reinforces the idea that inflammation may be related to the pathophysiology of progressive renal disease. Clin J Am Soc Nephrol 4: 1811-1817, 2009. doi: 10.2215/CJN.03510509

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease

Yan Liang, Jun Zhu, Lisheng Liu, Sonia S. Anand, Stuart J. Connolly, Jackie Bosch, Tomasz J. Guzik, Martin O'Donnell, Gilles R. Dagenais, Keith Aa Fox, Olga Shestakovska, Scott D. Berkowitz, Eva Muehlhofer, Lars Keller, Salim Yusuf, John W. Eikelboom

Summary: In patients with stable coronary artery disease or peripheral artery disease, the combination of rivaroxaban (2.5 mg twice daily) and aspirin compared with aspirin alone appears to produce consistent benefits in women and men, independent of baseline cardiovascular risk. There was no significant interaction between randomized treatment and baseline cardiovascular risk for major adverse cardiovascular events or major bleeding.

CARDIOVASCULAR RESEARCH (2021)

Article Cardiac & Cardiovascular Systems

The COMPASS Trial Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease

Jan Steffel, John W. Eikelboom, Sonia S. Anand, Olga Shestakovska, Salim Yusuf, Keith A. A. Fox

CIRCULATION (2020)

Article Cardiac & Cardiovascular Systems

Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction

John Hung, Andreas Roos, Erik Kadesjo, David A. McAllister, Dorien M. Kimenai, Anoop S. Shah, Atul Anand, Fiona E. Strachan, Keith A. A. Fox, Nicholas L. Mills, Andrew R. Chapman, Martin J. Holzmann

Summary: The GRACE 2.0 score showed good discrimination for predicting all-cause death at 1 year in patients with type 1 myocardial infarction, but only moderate discrimination for those with type 2 myocardial infarction.

EUROPEAN HEART JOURNAL (2021)

Article Cardiac & Cardiovascular Systems

Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization

Guillaume Marquis-Gravel, Megan L. Neely, Marco Valgimigli, Francesco Costa, David Van Klaveren, Rituparna Altner, Deepak L. Bhatt, Paul W. Armstrong, Keith A. A. Fox, Harvey D. White, E. Magnus Ohman, Matthew T. Roe

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2020)

Article Cardiac & Cardiovascular Systems

Machine learning does not improve upon traditional regression in predicting outcomes in atrial fibrillation: an analysis of the ORBIT-AF and GARFIELD-AF registries

Zak Loring, Suchit Mehrotra, Jonathan P. Piccini, John Camm, David Carlson, Gregg C. Fonarow, Keith A. A. Fox, Eric D. Peterson, Karen Pieper, Ajay K. Kakkar

EUROPACE (2020)

Article Cardiac & Cardiovascular Systems

2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group

Francois Schiele, Suleman Aktaa, Xavier Rossello, Ingo Ahrens, Marc J. Claeys, Jean-Philippe Collet, Keith A. A. Fox, Chris P. Gale, Kurt Huber, Zaza Iakobishvili, Alan Keys, Ekaterini Lambrinou, Sergio Leonardi, Maddalena Lettino, Frederick A. Masoudi, Susanna Price, Tom Quinn, Eva Swahn, Holger Thiele, Adam Timmis, Marco Tubaro, Christiaan J. M. Vrints, David Walker, Hector Bueno, Sigrun Halvorsen, Tomas Jernberg, Jarle Jortveit, Mai Blondal, Borja Ibanez, Christian Hassager

Summary: Updated quality indicators for the management of acute myocardial infarction were developed based on contemporary knowledge and accumulated experience, aiming to evaluate and improve the quality of care for myocardial infarction.

EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE (2021)

Article Hematology

Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry

Jean-Pierre Bassand, Saverio Virdone, Marc Badoz, Freek W. A. Verheugt, A. John Camm, Frank Cools, Keith A. A. Fox, Samuel Z. Goldhaber, Shinya Goto, Sylvia Haas, Werner Hacke, Gloria Kayani, Frank Misselwitz, Karen S. Pieper, Alexander G. G. Turpie, Martin van Eickels, Ajay K. Kakkar

Summary: In patients with atrial fibrillation, NOACs show lower risks of bleeding and all-cause mortality compared to VKAs, with major bleeding associated with the highest risk of death. Minor bleeding and CRNM bleeding are also linked to a higher risk of death compared to no bleeding. A significant percentage of deaths within 30 days after a major bleed are due to intracranial/intraspinal hemorrhage.

BLOOD ADVANCES (2021)

Article Cardiac & Cardiovascular Systems

Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial

Matthew A. Cavender, Michelle L. O'Donoghue, Antonio Abbate, Philip Aylward, Keith Aa Fox, Ruchira X. Glaser, Jeong-Gun Park, Jose Lopez-Sendon, Ph Gabriele Steg, Marc S. Sabatine, David A. Morrow

Summary: Losmapimod attenuated inflammatory response in patients with STEMI but not in those with NSTEMI. Differences in outcomes between the two patient groups suggest a potential need for separate strategies in managing inflammation in MI, with a stronger focus on heart failure.

AMERICAN HEART JOURNAL (2022)

Article Cardiac & Cardiovascular Systems

Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial

Pishoy Gouda, Chinthanie Ramasundarahettige, Sonia Anand, Eva Muhlhoffer, Scott Berkowitz, Keith Aa Fox, John Eikelboom, Robert Welsh

Summary: This study assessed clinical factors predicting the presence of PAD in patients with CAD, revealing that routinely available clinical information has limited utility in identifying patients with CAD and concomitant PAD.

ATHEROSCLEROSIS (2021)

Article Cardiac & Cardiovascular Systems

Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials

Sonia S. Anand, Will Hiatt, Leanne Dyal, Rupert Bauersachs, Scott D. Berkowitz, Kelley R. H. Branch, Sebastian Debus, Keith A. A. Fox, Yan Liang, Eva Muehlhofer, Mark Nehler, Lloyd P. Haskell, Manesh Patel, Michael Szarek, Salim Yusuf, John Eikelboom, Marc P. Bonaca

Summary: Among peripheral artery disease (PAD) patients, low-dose rivaroxaban plus aspirin is superior to aspirin alone in reducing cardiovascular and limb events, including acute limb ischemia and major vascular amputation. Despite an increased risk of major bleeding, there is no significant increase in severe bleeding with the combination therapy.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)

Article Cardiac & Cardiovascular Systems

GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation

Keith A. A. Fox, Saverio Virdone, Karen S. Pieper, Jean-Pierre Bassand, A. John Camm, David A. Fitzmaurice, Samuel Z. Goldhaber, Shinya Goto, Sylvia Haas, Gloria Kayani, Ali Oto, Frank Misselwitz, Jonathan P. Piccini, Frederik Dalgaard, Alexander G. G. Turpie, Freek W. A. Verheugt, Ajay K. Kakkar

Summary: This study confirms the effectiveness of the GARFIELD-AF integrated risk tool in predicting mortality, stroke, and bleeding in patients with atrial fibrillation, and compares it with the traditional predictors CHA(2)DS(2)-VASc and HAS-BLED.

EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2022)

Article Medicine, General & Internal

Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry

Keith A. A. Fox, Saverio Virdone, Jean-Pierre Bassand, A. John Camm, Shinya Goto, Samuel Z. Goldhaber, Sylvia Haas, Gloria Kayani, Yukihiro Koretsune, Frank Misselwitz, Seil Oh, Jonathan P. Piccini, Alex Parkhomenko, Jitendra Pal Singh Sawhney, Janina Stepinska, Alexander G. G. Turpie, Freek W. A. Verheugt, Ajay K. Kakkar

Summary: The variability in outcomes for patients with newly diagnosed AF across countries cannot be explained by baseline characteristics and antithrombotic treatments. Mortality rates are correlated with Healthcare Access and Quality indices.

BMJ OPEN (2022)

Letter Cardiac & Cardiovascular Systems

Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis

Nana Pogosova, Jacqueline Bosch, Deepak L. Bhatt, Keith A. A. Fox, Stuart J. Connolly, Marco Alings, Peter Verhamme, Eva Muehlhofer, Olga Shestakovska, Salim Yusuf, John W. Eikelboom

CIRCULATION (2022)

Article Cardiac & Cardiovascular Systems

Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF

Josephine Harrington, Anthony P. Carnicelli, Kaiyuan Hua, Lars Wallentin, Manesh R. Patel, Stefan H. Hohnloser, Robert P. Giugliano, Keith A. A. Fox, Ziad Hijazi, Renato D. Lopes, Sean D. Pokorney, Hwanhee Hong, Christopher B. Granger

Summary: Through meta-analysis of multiple research databases, it was found that standard-dose DOACs are safer and more effective than warfarin in patients with kidney dysfunction. While lower-dose DOACs do not significantly lower the incidence of bleeding or intracranial hemorrhage compared to standard-dose DOACs, they are associated with a higher incidence of stroke and systemic embolism as well as death. Therefore, these findings support the use of standard-dose DOACs over warfarin in patients with kidney dysfunction.

CIRCULATION (2023)

Editorial Material Cardiac & Cardiovascular Systems

Towards personalized cardiovascular care: Global Registry of Acute Coronary Events 3.0 score heralds artificial intelligence era

Florian A. Wenzl, Keith A. A. Fox, Thomas F. Luescher

EUROPEAN HEART JOURNAL (2023)

No Data Available